Timely review 📖 @DrAMansouri
mIDH inhibitors like vorasidenib delay progression in IDH-mut gliomas, but data on survival, QoL & cognition still lacking.
Proton therapy? Promising in theory.
We need to stay focused on what matters 🧠👥
🔗 https://t.co/QQ9OT4TxLC
#braincancer
Bare en påminnelse om at Norge har flere helsedirektører (333) enn intensivplasser (278).
Helt hundre prosent fullstendig klin kokos.
https://t.co/dfGbWkDXxw
Thousands of Danish citizens are launching an effort to buy California as a response to Trump’s attempt to take Greenland.
They say they will provide Californians with “rule of law, universal health care, fact-based politics, and a lifetime supply of Danish pastries.”
#OnlineFirst: Prognostic value of manual versus automatic methods for assessing extents of resection and residual tumor volume in glioblastoma.
https://t.co/JRKsc6lZ42.
🔍 New study reveals 78.9% of spinal cord stimulation RCTs reported conflicts of interest (COIs), with 76.3% having undisclosed COIs.
This calls for stronger COI policies to uphold integrity in neuromodulation research.
https://t.co/10ASiahKDj
@Ryan_S_DSouzaMD@JohanaKlasova
@clemensweber A very overtreated fracture. In low energy type 2 fractures, do patients even need collars? Most of these are osteoporotic fractures in the elderly that never heal - and it does not really matter. Few have plan and late myelopathy is never seen.
Is decompression alone non-inferior to decompression with instrumented fusion in patients with degenerative lumbar spondylolisthesis?
New randomised trial investigates @AustevollIvar
https://t.co/RUaPOukO8J
Exciting News! Vorasidenib (brand name: Voranigo) has just been approved by the FDA for the treatment of adult and pediatric patients 12 years of age and older with grade 2 astrocytoma or oligodendroglioma with an IDH1 or IDH2 mutation. Read more: https://t.co/G6FB95R7nj
@NaderSanai@MTouatMD Since the RTOG9802 trial from 2016 the evidence for RT/PCV has been far stronger than for RT/TMZ. Still, many have chosen the latter as standard treatment. This has not been evidence based practice, and as seen, not benefical for the patients.
Another example of medicalisation of suffering when a medical response is not the best response. (Shameful as well that basic data on age and gender are missing.) https://t.co/sMp9ibFCX0
CAR-T kills more people early
Population was *NOT* heavily pretreated
OS is not significantly improved
Data are too immature for OS analysis
What does the FDA do?
11-0!
If anything, with emerging alternative options, CAR-T should move BACK in lines of therapy
8-3 vote on a IDA Cel
Drug doesn't improve survival
Clearly OS curves look like they will never be positive
Tons of toxicity, early death
Astonishingly low standards in Cancer medicine
Patients with evidence of microplastics and nanoplastics in carotid artery plaque, as compared with patients without, had a greater risk of adverse cardiovascular events at 34 months of follow-up. Read the full article: https://t.co/BUsdzHMcdb
Looking forward to meet Scandinavian/Nordic neuro-oncology friends in April 🇫🇮🇩🇰🇸🇪 🇳🇴🇮🇸: https://t.co/4STt2UwbjR Present, interact, collaborate, socialize👩⚕️👨🏾🎓👩🏼💻👩🏾🔬👨🏻🏫at this exciting newly opened venue: https://t.co/043mK8mFFx